Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AZP-531: Additional Phase II data

    Alize Pharma, Lyon, France Product: AZP-531 Business: Endocrine/Metabolic Molecular target: Ghrelin Description: Unacylated ghrelin analog Indication: Treat Prader-Willi syndrome Endpoint: Safety; effects on fullness/…

    Published on 5/2/2016
  • Cabometyx cabozantinib: Additional Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Ipsen Group (Euronext:IPN), Boulogne-Billancourt, France Product: Cabometyx cabozantinib (Cometriq) (XL184) Business: Cancer Molecular target: Vascular …

    Published on 5/2/2016
  • Entinostat: Phase I/II data

    Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), Waltham, Mass. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Entinostat (SNDX-275) (formerly MS-275) Business: Cancer Molecular target: Histone deacetylase (HDAC) …

    Published on 5/2/2016
  • Erbitux cetuximab: Phase III data

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Erbitux cetuximab Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Chimeric …

    Published on 5/2/2016
  • FBP vaccine: Additional Phase IIa data

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: FBP vaccine (GALE-301) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP) vaccine Indication: …

    Published on 5/2/2016
  • GALE-302: Additional Phase IIa data

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: GALE-302 (formerly J65) Business: Cancer Molecular target: NA Description: Attenuated folate binding protein-E39 (FBP) vaccine Indication: Prevent recurrence …

    Published on 5/2/2016
  • Glycopyrrolate: Phase III data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Glycopyrrolate (SUN-101) (formerly EP-101) Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled formulation of …

    Published on 5/2/2016
  • Lenti-D gene therapy: Additional Phase II/III data

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: Lenti-D gene therapy Business: Neurology Molecular target: NA Description: Hematopoietic stem cell therapy with a lentiviral vector delivering the wild-type …

    Published on 5/2/2016
  • PBI-4050: Additional Phase II data

    ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Product: PBI-4050 Business: Endocrine/Metabolic Molecular target: NA Description: Oral anti-fibrotic compound Indication: Treat Type II diabetics with …

    Published on 5/2/2016
  • Sacituzumab govitecan: Additional Phase I/II data

    Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Sacituzumab govitecan (hRS7-SN-38) (IMMU-132) Business: Cancer Molecular target: Epithelial glycoprotein-1 (EGP-1) Description: Humanized antibody against …

    Published on 5/2/2016
  • Simeprevir: Phase III data

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Simeprevir (Sovriad, Galexos, Olysio) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 5/2/2016
  • Subcutaneous semaglutide: Phase IIIa data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Subcutaneous semaglutide (NN9535) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Long-…

    Published on 5/2/2016
  • Talazoparib: Phase I data

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Product: Talazoparib (MDV3800) (formerly LT-673, BMN 673, BMN-673) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Poly(ADP-ribose)…

    Published on 5/2/2016
  • Tenofovir alafenamide fumarate: Additional Phase III data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Tenofovir alafenamide fumarate (TAF) (GS-7340) Business: Infectious Molecular target: NA Description: Prodrug of tenofovir, a nucleotide analog prodrug …

    Published on 5/2/2016
  • Tenofovir alafenamide fumarate: Additional Phase III data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Tenofovir alafenamide fumarate (TAF) (GS-7340) Business: Infectious Molecular target: NA Description: Prodrug of tenofovir, a nucleotide analog prodrug …

    Published on 5/2/2016
  • Zuprata: Preliminary Phase II data

    Clearside Biomedical Inc., Alpharetta, Ga. Product: Zuprata (CLS-TA, CLS-1001) Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Triamcinolone acetonide delivered using the companys …

    Published on 5/2/2016
  • ABT-493: Additional Phase IIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-493 Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Next-generation HCV NS3…

    Published on 4/25/2016
  • ABT-493: Additional Phase IIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-493 Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Next-generation HCV NS3…

    Published on 4/25/2016
  • ABT-530: Additional Phase IIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-530 Business: Infectious Molecular target: HCV NS5A protein Description: Next-generation HCV NS5A protein inhibitor Indication: Treat chronic HCV infection Endpoint: …

    Published on 4/25/2016
  • ABT-530: Additional Phase IIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-530 Business: Infectious Molecular target: HCV NS5A protein Description: Next-generation HCV NS5A protein inhibitor Indication: Treat chronic HCV genotypes 2 and 3 …

    Published on 4/25/2016
  • Bimagrumab: Phase II/III data

    MorphoSys AG (Xetra:MOR), Martinsried, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Bimagrumab (BYM338) Business: Musculoskeletal Molecular target: Activin receptor type 2B (ACVR2B) Description:…

    Published on 4/25/2016
  • BMN 270: Preliminary Phase I/II data

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Product: BMN 270 Business: Hematology Molecular target: Factor VIII Description: Adeno-associated viral (AAV) vector delivering the Factor VIII gene …

    Published on 4/25/2016
  • Brigatinib: Additional Phase I/II data

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: Brigatinib (AP26113) Business: Cancer Molecular target: Anaplastic lymphoma kinase (ALK); Epidermal growth factor receptor (EGFR) Description: Dual …

    Published on 4/25/2016
  • Cobiprostone: Phase IIa discontinued

    Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP), Bethesda, Md. Product: Cobiprostone (SPI-8811) (formerly RU-8811) Business: Gastrointestinal Molecular target: Chloride channel 2 (CLCN2) (ClC-2) Description: Prostone …

    Published on 4/25/2016
  • Deflazacort: Phase III data

    Marathon Pharmaceuticals LLC, Northbrook, Ill. Product: Deflazacort (MP-104) Business: Musculoskeletal Molecular target: NA Description: Glucocorticoid with anti-inflammatory and immunosuppressant properties Indication:…

    Published on 4/25/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993